BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 16452184)

  • 1. Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis.
    Kurban G; Hudon V; Duplan E; Ohh M; Pause A
    Cancer Res; 2006 Feb; 66(3):1313-9. PubMed ID: 16452184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Collagen matrix assembly is driven by the interaction of von Hippel-Lindau tumor suppressor protein with hydroxylated collagen IV alpha 2.
    Kurban G; Duplan E; Ramlal N; Hudon V; Sado Y; Ninomiya Y; Pause A
    Oncogene; 2008 Feb; 27(7):1004-12. PubMed ID: 17700531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JunB promotes cell invasion and angiogenesis in VHL-defective renal cell carcinoma.
    Kanno T; Kamba T; Yamasaki T; Shibasaki N; Saito R; Terada N; Toda Y; Mikami Y; Inoue T; Kanematsu A; Nishiyama H; Ogawa O; Nakamura E
    Oncogene; 2012 Jun; 31(25):3098-110. PubMed ID: 22020339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
    Siemeister G; Weindel K; Mohrs K; Barleon B; Martiny-Baron G; Marmé D
    Cancer Res; 1996 May; 56(10):2299-301. PubMed ID: 8625303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation.
    He Z; Liu S; Guo M; Mao J; Hughson MD
    Cancer Genet Cytogenet; 2004 Jul; 152(2):89-94. PubMed ID: 15262424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
    Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
    Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.
    Zimmer M; Doucette D; Siddiqui N; Iliopoulos O
    Mol Cancer Res; 2004 Feb; 2(2):89-95. PubMed ID: 14985465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
    Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
    Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME.
    Tedesco L; Elguero B; Pacin DG; Senin S; Pollak C; Garcia Marchiñena PA; Jurado AM; Isola M; Labanca MJ; Palazzo M; Yankilevich P; Fuertes M; Arzt E
    Cell Death Dis; 2019 Mar; 10(4):266. PubMed ID: 30890701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
    Petrella BL; Lohi J; Brinckerhoff CE
    Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tumor suppressor gene VHL, hypoxia inducible factor, and renal cell carcinoma].
    Zhang YT; Chen N; Zeng H; Zhou Q
    Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):562-4. PubMed ID: 17134554
    [No Abstract]   [Full Text] [Related]  

  • 14. EAF2 loss enhances angiogenic effects of Von Hippel-Lindau heterozygosity on the murine liver and prostate.
    Pascal LE; Ai J; Rigatti LH; Lipton AK; Xiao W; Gnarra JR; Wang Z
    Angiogenesis; 2011 Sep; 14(3):331-43. PubMed ID: 21638067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase.
    Petrella BL; Brinckerhoff CE
    Mol Cancer; 2006 Dec; 5():66. PubMed ID: 17140440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms.
    Calzada MJ; Esteban MA; Feijoo-Cuaresma M; Castellanos MC; Naranjo-Suárez S; Temes E; Méndez F; Yánez-Mo M; Ohh M; Landázuri MO
    Cancer Res; 2006 Feb; 66(3):1553-60. PubMed ID: 16452212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development.
    Stickle NH; Chung J; Klco JM; Hill RP; Kaelin WG; Ohh M
    Mol Cell Biol; 2004 Apr; 24(8):3251-61. PubMed ID: 15060148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
    Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
    Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
    Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo.
    Gross DJ; Reibstein I; Weiss L; Slavin S; Dafni H; Neeman M; Pines M; Nagler A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3788-93. PubMed ID: 14506172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.